The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Prognostic value of body weight loss in previously treated metastatic gastric cancer
Michele Ghidini, MD, PhD, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy, discusses the results of a post-hoc analysis of the Phase III TAGS trial (NCT02500043), evaluating trifluridine/tipiracil in patients with metastatic gastric adenocarcinoma. In this retrospective analysis, body weight loss was found to negatively associate with survival outcomes in gastric cancer patients receiving third- or later-line treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
